Great news for all shareholders, flash market research (google them) did a new profile on ARRY. I made $140k over the summer on their research report picks, so this is not something to take lightly. I expect a solid increase in volume this week. Glad to be a shareholder here!
Because this isn't their baby. ONT-380 (also known as ARRY-380) is an orally active, reversible and selective small-molecule HER2 inhibitor being developed by Oncothyreon in collaboration with Array BioPharma Inc. (Nasdaq: ARRY), Boulder, Colorado.